Company / Interest Expense
GT Biopharma, Inc. Interest Expense History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
-$2.1M
FY2020
5-year range
-$2.1M / $17.0M
FY2016-FY2020
Trend
-132.5%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense has fluctuated over the past 8 years, ranging from -$2M in FY2020 to $17M in FY2016.
Based on SEC 10-K filings.
-$2M in FY2020.
Improved from $17M to -$2M over the past 4 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, interest expense decreased 132.5% year-over-year.
- Peak interest expense was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$2.1M | -132.5% |
| FY2017 | $6.6M | -61.5% |
| FY2016 | $17.0M | +231.1% |
| FY2015 | $5.1M | +330.3% |
| FY2014 | $1.2M | -27.6% |
| FY2013 | $1.7M | +197.3% |
| FY2012 | $556.0K | +8.4% |
| FY2011 | $513.0K | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026